UE – co-financed projects implemented

Preclinical and clinical development of a first-in-class, innovative, bispecific immunotherapeutic agent as a drug candidate in cancer immunotherapy 

Development of an innovative, class-leading, low-molecular, double-oriented therapeutic agent having immunomodulating and cytotoxic effects as a drug candidate for the treatment of leukaemia and solid tumours

Development of an innovative platform for the production of bispecific constructions based on Phage Display technique and the preclinical and clinical development of an innovative bispecific drug candidate for the treatment of inflammatory diseases

Preclinical and clinical development of the innovative PI3 delta kinase inhibitor as a candidate in the treatment of inflammatory diseases

UBA – Preclinical and clinical development of the ubiquitin-proteasome system inhibitor as an innovative drug used in cancer treatment.

AMDBP – Development of a production platform for biosimilars based on CHO cells and an innovative expression system and preclinical and clinical development of a biosimilar drug based on a Fab fragment.

GATE – Preclinical and clinical development of an innovative antagonist of GPR40 receptor in type 2 diabetes treatment

FAIND – A new diabetes treatment using an innovative FGF1 protein analogue.

A new form of S-ketamine in treatment of depression